Authors
Ryutaro Yamaguchi, Yosuke Tamura, Yuki Asai, Kazuhiro Takezaki, Akira Yura, Hideaki Kawaguchi, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Kenjiro Tsuruoka, Takahiko Nakamura, Soichiro Ikeda, Yasuhito Fujisaka
Published in
Internal medicine (Tokyo, Japan). Jul 04, 2026. Epub Jul 04, 2026.
Abstract
Cancer-related pain affects more than 70% of patients with advanced cancer and it is mediated by tumor invasion and inflammatory cytokine-induced neural sensitization. Anticancer therapies may transiently exacerbate pain through treatment-related inflammatory responses. Amivantamab, an EGFR-MET bispecific antibody approved for EGFR-mutated non-small cell lung cancer, commonly causes infusion-related reactions (IRRs), typically with flushing or respiratory symptoms. We report a case of a 70-year-old woman with EGFR-mutated lung adenocarcinoma who developed a reproducible, transient exacerbation of pre-existing cancer-related pain during initial amivantamab infusions without any systemic abnormalities or clear evidence of radiologic progression. This suggests that acute pain flare is an atypical manifestation of amivantamab-induced IRR.
PMID:
42402398
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0